Catalog No.
AID00801
Expression system
Confidential
Species
Homo sapiens (Human)
Protein length
Confidential
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q03001
Applications
As a diagnostic tool for Bullous pemphigoid (BP).
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Bullous pemphigoid antigen, 230 kDa bullous pemphigoid antigen, BPAG1, Bullous pemphigoid antigen 1, Dystonin, BP230, DT, Hemidesmosomal plaque protein, DMH, KIAA0728, DST, BPA, BP240, Dystonia musculorum protein, 230/240 kDa bullous pemphigoid antigen
Aberrant glycosylation patterns as potential biomarkers for diagnosis and disease progression in bullous pemphigoid., PMID:40491922
Autosomal recessive epidermolysis bullosa simplex due to compound heterozygous mutations in DST gene: first Italian case and literature review., PMID:40371845
Localization of Lesions in Autoimmune Blistering Diseases Is Independent of Site-Specific Target Antigen Expression., PMID:40003627
Periostin in Bullous Pemphigoid: A Potential Biomarker of Disease Activity and Severity., PMID:39989295
Bullous pemphigoid., PMID:39979318
Diagnostic methods and strategies for autoimmune bullous diseases., PMID:39930606
Correlation of BP180, BP230, and type VII collagen antibody titers in serum, blister fluid, erosion, and saliva in pemphigoid diseases., PMID:39916594
Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases., PMID:39877369
Clinical characteristics of bullous pemphigoid patients of different ages and the possible mechanism., PMID:39821084
Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230., PMID:39676877
Use of multivariant enzyme-linked immunosorbent assay (ELISA) in the diagnosis of autoimmune bullous disorders in a resource-limited setting: A single-center experience., PMID:39635793
Ocular Mucous Membrane Pemphigoid Demonstrates a Distinct Autoantibody Profile from Those of Other Autoimmune Blistering Diseases: A Preliminary Study., PMID:39584991
The "entanglement" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations., PMID:39521622
Clinical manifestation variability of bullous pemphigoid., PMID:39487837
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)., PMID:39425892
Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis., PMID:39356527
The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance., PMID:39267741
Junctional Epidermolysis Bullosa in Sprague Dawley Rats Caused by a Frameshift Mutation of Col17a1 Gene., PMID:39265891
Polarization of circulating follicular helper T cells correlates with bullous pemphigoid severity., PMID:39255051
The Role of Serology in the Diagnosis of Ocular Predominant Mucous Membrane Pemphigoid and the Search for an Ocular-Specific Autoantigen., PMID:39241171
Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity., PMID:38582700
Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study., PMID:38389191
Expression of Serum Anti-BP180/230 Antibodies in Bullous Pemphigoid Patients Combined with Nervous System Diseases and Relevant Factor Analysis., PMID:38342861
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update., PMID:38157140
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid., PMID:38069109
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches., PMID:37897588
[Management of bullous pemphigoid and mucous membrane pemphigoid]., PMID:37843581
The Eotaxin-1/CCR3 Axis and Matrix Metalloproteinase-9 Are Critical in Anti-NC16A IgE-Induced Bullous Pemphigoid., PMID:37672029
Roles of dystonin isoforms in the maintenance of neural, muscle, and cutaneous tissues., PMID:37603210
Evaluation of Dupilumab in Patients With Bullous Pemphigoid., PMID:37531116
Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid., PMID:37509055
Case Report: Prurigo nodularis-like linear IgA/IgG bullous dermatosis: a case report and literature review., PMID:37325615
Mixed muco-cutaneous pemphigoid: Clinical and immunological features of 15 cases., PMID:37006294
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid., PMID:36999962
Research progress of omalizumab in the treatment of bullous pemphigoid., PMID:36971190
Nail abnormalities in subepidermal blistering diseases: a cross-sectional study., PMID:36951363
Interleukin-36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid., PMID:36940975
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid., PMID:36937423
Disease Endotypes Predict the Severity of Mucous Membrane Pemphigoid., PMID:36870557
Lichen Planopilaris Pemphigoides: A Novel Bullous Dermatosis Due to Programmed Cell Death Protein-1 Inhibitor Therapy., PMID:36825932
Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients., PMID:36763158
Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis., PMID:36569153
Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients., PMID:36466856
Utility of the pattern-based approach using BIOCHIP-indirect immunofluorescence in the evaluation of subepidermal bullous disorders., PMID:36444506
What's new in the pathogeneses and triggering factors of bullous pemphigoid., PMID:36412277
Bullous pemphigoid-What do we know about the most recent therapies?, PMID:36405625
Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's disease., PMID:36341270
A case of dipeptidyl peptidase-4 inhibitor-related anti-BP230-type bullous pemphigoid showing granular C3 dermatosis-like direct immunofluorescence staining., PMID:36301770
Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid., PMID:36259470
A Case of Anti-BP180-type Mucous Membrane Pemphigoid with IgG and IgA Autoantibodies Showing Distinct Reactivities., PMID:36153720
For research use only. Not for human or drug use.
